ArticleMedicine2026

Post-marketing safety of ensifentrine in COPD: A retrospective pharmacovigilance study using disproportionality analysis of FAERS/AEMS reports.

Fatma Özge YağbasanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.